6505--Diclofenac Sodium (NA) 1% Gel
ID: 36E79725R0012Type: Solicitation
AwardedJul 2, 2025
$63.1M$63,068,832
AwardeeEXELAN PHARMACEUTICALS INC BOCA RATON 33432-5826 FLK
Award #:36E79725D0047
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/421859c493af4c1fb6c3d7cfef06934f/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Diclofenac Sodium (NA) 1% Gel, intended for use in its pharmaceutical programs as well as those of the Department of Defense (DoD). Contractors are required to provide pricing for a base year along with four one-year option years, ensuring compliance with federal drug regulations and the Drug Supply Chain Security Act (DSCSA). This procurement is critical for maintaining a reliable supply of pharmaceutical products that meet stringent manufacturing standards and public health requirements. Interested parties must submit their offers by March 4, 2025, at 2:30 PM Central Time, and can contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further information.

    Point(s) of Contact
    Ray RoldanContract Specialist
    Raymond.Roldan@va.gov
    Files
    Title
    Posted
    36E79725R0012.docx
    The document outlines a Request for Proposals (RFP) issued by the Department of Veterans Affairs (VA) for the supply of Diclofenac NA 1% Gel for the VA and Department of Defense (DoD) pharmaceutical programs. Key points include the requirement for potential contractors to provide pricing for a base year and four one-year option years, with specific instructions for submitting offers and samples. The contractor must adhere to established federal drug regulations and supply chain guidelines, including compliance with the Drug Supply Chain Security Act (DSCSA). The contract will be effective upon signing and will have set delivery and payment terms, with a unique focus on small businesses, including categories like women-owned and service-disabled veteran-owned businesses. The document emphasizes adherence to stringent manufacturing standards and the need for submitted products to have identifiable National Drug Codes (NDCs) or Universal Product Codes (UPCs). It highlights the government's commitment to maintaining compliance while ensuring consistent product availability through its prime vendor network. This RFP illustrates the structured process by which government contracts for pharmaceutical products are awarded, underscoring the criticality of compliance with regulatory standards designed to protect public health and ensure quality supply chains.
    36E79725R0012 0001.docx
    The document is an amendment related to solicitation 36E79725R0012 for the procurement of Diclofenac Gel, issued by the Department of Veterans Affairs National Acquisition Center. The primary purpose of this amendment is to extend the deadline for submission of offers from February 25, 2025, to March 4, 2025, at 2:30 PM Central Time. The amendment stipulates that all other terms and conditions of the solicitation remain unchanged. The document specifies methods by which offerors can acknowledge receipt of the amendment, including providing signed copies or references in their submissions. The contracting officer responsible for this amendment is Nicholas I. McGregor, indicating formal oversight of the solicitation process. This document exemplifies typical practices and procedures in federal government contracting, highlighting the importance of deadlines and compliance with solicitation amendments in securing government contracts.
    Similar Opportunities
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal acquisition regulations and ethical standards. Metaxalone is a critical medication used for muscle relaxation, making this contract vital for supporting military health services. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST. For further inquiries, contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Tretinoin Cream
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Tretinoin Cream. The cream is used for various dermatological conditions and comes in different strengths (0.025%, 0.05%, and 0.1%) and tube sizes (20G and 45G). The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. It will establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. Interested parties should contact Ryan Ferry for more information. The projected solicitation date is February 2023.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.